These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

228 related articles for article (PubMed ID: 15956232)

  • 1. Tinzaparin in outpatients with pulmonary embolism or deep vein thrombosis.
    Dager WE; King JH; Branch JM; Chow SL; Ferrer RE; Pak S; Togioka PY; White RH
    Ann Pharmacother; 2005; 39(7-8):1182-7. PubMed ID: 15956232
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tinzaparin sodium: a low-molecular-weight heparin.
    Neely JL; Carlson SS; Lenhart SE
    Am J Health Syst Pharm; 2002 Aug; 59(15):1426-36. PubMed ID: 12166042
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A comparison of low-molecular-weight heparin with unfractionated heparin for acute pulmonary embolism. The THESEE Study Group. Tinzaparine ou Heparine Standard: Evaluations dans l'Embolie Pulmonaire.
    Simonneau G; Sors H; Charbonnier B; Page Y; Laaban JP; Azarian R; Laurent M; Hirsch JL; Ferrari E; Bosson JL; Mottier D; Beau B
    N Engl J Med; 1997 Sep; 337(10):663-9. PubMed ID: 9278462
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Expanding eligibility for outpatient treatment of deep venous thrombosis and pulmonary embolism with low-molecular-weight heparin: a comparison of patient self-injection with homecare injection.
    Wells PS; Kovacs MJ; Bormanis J; Forgie MA; Goudie D; Morrow B; Kovacs J
    Arch Intern Med; 1998 Sep; 158(16):1809-12. PubMed ID: 9738611
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Outpatient treatment of pulmonary embolism with dalteparin.
    Kovacs MJ; Anderson D; Morrow B; Gray L; Touchie D; Wells PS
    Thromb Haemost; 2000 Feb; 83(2):209-11. PubMed ID: 10739374
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Structured benefit-risk assessment for enoxaparin, in the context of its label extension, for the extended treatment of deep vein thrombosis and pulmonary embolism, and prevention of its recurrence in patients with active cancer.
    Kürzinger ML; El-Haddad C; Gouin-Soboleva T; Fazekas Z; Granados D; Benito-Garcia E; Djoudi Y
    Pharmacoepidemiol Drug Saf; 2024 May; 33(5):e5795. PubMed ID: 38680090
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tinzaparin in the treatment of venous thromboembolism.
    Pineo GF; Hull RD
    Expert Opin Pharmacother; 2003 Dec; 4(12):2355-62. PubMed ID: 14640933
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Outpatient treatment of acute venous thromboembolic disease.
    Yusen RD; Gage BF
    Clin Chest Med; 2003 Mar; 24(1):49-61. PubMed ID: 12685056
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The outpatient bleeding risk index: validation of a tool for predicting bleeding rates in patients treated for deep venous thrombosis and pulmonary embolism.
    Wells PS; Forgie MA; Simms M; Greene A; Touchie D; Lewis G; Anderson J; Rodger MA
    Arch Intern Med; 2003 Apr; 163(8):917-20. PubMed ID: 12719200
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Outpatient management of venous thromboembolism.
    Vanscoy GJ
    J Thromb Thrombolysis; 1999 Apr; 7(2):109-12. PubMed ID: 10364775
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of six-month outcome of patients initially treated for acute deep vein thrombosis with a low molecular weight heparin Certoparin at a fixed, body-weight-independent dosage or unfractionated heparin.
    Harenberg J; Riess H; Büller HR; Brom J; Weidinger G; Huisman MV
    Haematologica; 2003 Oct; 88(10):1157-62. PubMed ID: 14555312
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Outpatient treatment in patients with acute pulmonary embolism: the Hestia Study.
    Zondag W; Mos IC; Creemers-Schild D; Hoogerbrugge AD; Dekkers OM; Dolsma J; Eijsvogel M; Faber LM; Hofstee HM; Hovens MM; Jonkers GJ; van Kralingen KW; Kruip MJ; Vlasveld T; de Vreede MJ; Huisman MV;
    J Thromb Haemost; 2011 Aug; 9(8):1500-7. PubMed ID: 21645235
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Assessment of outpatient treatment of deep-vein thrombosis with low-molecular-weight heparin.
    Harrison L; McGinnis J; Crowther M; Ginsberg J; Hirsh J
    Arch Intern Med; 1998 Oct; 158(18):2001-3. PubMed ID: 9778199
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The use of antithrombotic drugs in older people.
    Tufano A; Cerbone AM; Di Minno G
    Minerva Med; 2002 Feb; 93(1):13-26. PubMed ID: 11850611
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Secondary prevention of venous thromboembolism: A role for low-molecular-weight heparin.
    Monreal M; Roncales FJ; Ruiz J; Muchart J; Fraile M; Costa J; Hernandez JA
    Haemostasis; 1998; 28(5):236-43. PubMed ID: 10420072
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antithrombotic therapy for VTE disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.
    Kearon C; Akl EA; Comerota AJ; Prandoni P; Bounameaux H; Goldhaber SZ; Nelson ME; Wells PS; Gould MK; Dentali F; Crowther M; Kahn SR
    Chest; 2012 Feb; 141(2 Suppl):e419S-e496S. PubMed ID: 22315268
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Longitudinal evaluation of health plan cost per venous thromboembolism or bleed event in patients with a prior venous thromboembolism event during hospitalization.
    Bullano MF; Willey V; Hauch O; Wygant G; Spyropoulos AC; Hoffman L
    J Manag Care Pharm; 2005 Oct; 11(8):663-73. PubMed ID: 16194130
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pathophysiology and treatment of deep-vein thrombosis and pulmonary embolism.
    Carter BL; Jones ME; Waickman LA
    Clin Pharm; 1985; 4(3):279-96. PubMed ID: 3891200
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Determinants of Late Venous Thromboembolic Events After Acute Isolated Superficial Vein Thrombosis in Daily Practice: 12 Month Results of the INSIGHTS-SVT Study.
    Rabe E; Hoffmann U; Schimke A; Heinken A; Langer F; Noppeney T; Pittrow D; Klotsche J; Gerlach HE; Bauersachs R;
    Eur J Vasc Endovasc Surg; 2023 Nov; 66(5):697-704. PubMed ID: 37573936
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Six-week low-molecular-weight heparin versus 12-week warfarin for calf deep vein thrombosis: A randomized, prospective, open-label study.
    Sartori M; Iotti M; Camporese G; Siragusa S; Imberti D; Bucherini E; Corradini S; Ageno W; Prandoni P; Ghirarduzzi A
    Am J Hematol; 2024 May; 99(5):854-861. PubMed ID: 38375893
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.